Inhibikase Therapeutics Company Insiders
| IKT Stock | USD 2.92 0.19 6.96% |
Inhibikase Therapeutics employs about 8 people. The company is managed by 8 executives with a total tenure of roughly 19 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Breaking down Inhibikase Therapeutics' management performance can provide insight into the firm performance.
Inhibikase |
Inhibikase Therapeutics Management Team Effectiveness
The company has Return on Asset of (0.7621) % which means that on every $100 spent on assets, it lost $0.7621. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.4969) %, meaning that it generated no profit with money invested by stockholders. Inhibikase Therapeutics' management efficiency ratios could be used to measure how well Inhibikase Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.38 in 2024. Return On Capital Employed is likely to gain to -1.72 in 2024. At this time, Inhibikase Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 18.3 M in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 85.6 K in 2024.Common Stock Shares Outstanding is likely to drop to about 3.2 M in 2024. Net Loss is likely to gain to about (12.6 M) in 2024
Inhibikase Therapeutics Workforce Comparison
Inhibikase Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 836. Inhibikase Therapeutics maintains roughly 8.0 in number of employees contributing less than 1% to equities under Health Care industry.
Inhibikase Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Inhibikase Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Inhibikase Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Inhibikase Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-06-01 | 2.0 | 2 | 1 | 135,000 | 5,834 |
| 2022-03-01 | 8.0 | 8 | 1 | 646,853 | 21,853 |
| 2021-09-01 | 1.0 | 1 | 1 | 21,853 | 21,853 |
| 2021-06-01 | 2.5 | 5 | 2 | 134,415 | 60,625 |
| 2020-12-01 | 0.7778 | 7 | 9 | 271,443 | 218,533 |
Inhibikase Therapeutics Notable Stakeholders
An Inhibikase Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Inhibikase Therapeutics often face trade-offs trying to please all of them. Inhibikase Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Inhibikase Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Milton Werner | President CEO | Profile | |
| Roger Rush | Head Research | Profile | |
| BSc FRCPC | Interim Advisor | Profile | |
| Garth LeesRolfe | Chief Officer | Profile | |
| Joseph CPA | Chief Officer | Profile | |
| Surendra Singh | Manufacturing Chemistry | Profile | |
| Dan Williams | Controller | Profile | |
| Garth CPA | Chief Officer | Profile |
About Inhibikase Therapeutics Management Performance
The success or failure of an entity such as Inhibikase Therapeutics often depends on how effective the management is. Inhibikase Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Inhibikase management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Inhibikase management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.31) | (1.38) | |
| Return On Capital Employed | (1.82) | (1.72) | |
| Return On Assets | (1.31) | (1.38) | |
| Return On Equity | (1.73) | (1.65) |
Please note, the imprecision that can be found in Inhibikase Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Inhibikase Therapeutics. Check Inhibikase Therapeutics' Beneish M Score to see the likelihood of Inhibikase Therapeutics' management manipulating its earnings.
Inhibikase Therapeutics Workforce Analysis
Traditionally, organizations such as Inhibikase Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Inhibikase Therapeutics within its industry.Inhibikase Therapeutics Manpower Efficiency
Return on Inhibikase Therapeutics Manpower
| Revenue Per Employee | 32.6K | |
| Revenue Per Executive | 32.6K | |
| Net Loss Per Employee | 2.4M | |
| Net Loss Per Executive | 2.4M | |
| Working Capital Per Employee | 1.3M | |
| Working Capital Per Executive | 1.3M |
Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.